Logo image of ACOG

ALPHA COGNITION INC (ACOG) Stock Fundamental Analysis

USA - NASDAQ:ACOG - CA02074J5017 - Common Stock

7.44 USD
+0.07 (+0.95%)
Last: 10/2/2025, 6:00:56 PM
7.3 USD
-0.14 (-1.88%)
After Hours: 10/2/2025, 6:00:56 PM
Fundamental Rating

3

ACOG gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 536 industry peers in the Biotechnology industry. While ACOG has a great health rating, there are worries on its profitability. ACOG does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ACOG had negative earnings in the past year.
ACOG had a negative operating cash flow in the past year.
ACOG had negative earnings in each of the past 5 years.
In the past 5 years ACOG always reported negative operating cash flow.
ACOG Yearly Net Income VS EBIT VS OCF VS FCFACOG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

The Return On Assets of ACOG (-44.35%) is comparable to the rest of the industry.
ACOG has a better Return On Equity (-62.75%) than 61.19% of its industry peers.
Industry RankSector Rank
ROA -44.35%
ROE -62.75%
ROIC N/A
ROA(3y)-333.55%
ROA(5y)-244.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ACOG Yearly ROA, ROE, ROICACOG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -10K -20K -30K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ACOG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACOG Yearly Profit, Operating, Gross MarginsACOG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

ACOG has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, ACOG has an improved debt to assets ratio.
ACOG Yearly Shares OutstandingACOG Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M
ACOG Yearly Total Debt VS Total AssetsACOG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

An Altman-Z score of 2.80 indicates that ACOG is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of ACOG (2.80) is better than 69.40% of its industry peers.
There is no outstanding debt for ACOG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.8
ROIC/WACCN/A
WACCN/A
ACOG Yearly LT Debt VS Equity VS FCFACOG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M 20M 30M 40M

2.3 Liquidity

A Current Ratio of 14.69 indicates that ACOG has no problem at all paying its short term obligations.
ACOG's Current ratio of 14.69 is amongst the best of the industry. ACOG outperforms 89.18% of its industry peers.
A Quick Ratio of 14.40 indicates that ACOG has no problem at all paying its short term obligations.
The Quick ratio of ACOG (14.40) is better than 89.18% of its industry peers.
Industry RankSector Rank
Current Ratio 14.69
Quick Ratio 14.4
ACOG Yearly Current Assets VS Current LiabilitesACOG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

ACOG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.08%, which is quite impressive.
EPS 1Y (TTM)38.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-160%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ACOG is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -275.00% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-1706.25%
EPS Next 2Y-275%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACOG Yearly Revenue VS EstimatesACOG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 10M 20M 30M
ACOG Yearly EPS VS EstimatesACOG Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2024 2025 2026 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACOG. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACOG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACOG Price Earnings VS Forward Price EarningsACOG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACOG Per share dataACOG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

ACOG's earnings are expected to decrease with -275.00% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-275%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACOG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALPHA COGNITION INC

NASDAQ:ACOG (10/2/2025, 6:00:56 PM)

After market: 7.3 -0.14 (-1.88%)

7.44

+0.07 (+0.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-18 2025-08-18/dmh
Earnings (Next)N/A N/A
Inst Owners35.39%
Inst Owner ChangeN/A
Ins Owners12.88%
Ins Owner Change-5.15%
Market Cap120.23M
Analysts82.86
Price Target20.4 (174.19%)
Short Float %0.36%
Short Ratio0.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)26.54%
Min EPS beat(2)-24.95%
Max EPS beat(2)78.03%
EPS beat(4)2
Avg EPS beat(4)36.98%
Min EPS beat(4)-24.95%
Max EPS beat(4)99.02%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)14.4%
Min Revenue beat(2)-14.76%
Max Revenue beat(2)43.56%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.16%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)33.99%
Revenue NY rev (1m)0%
Revenue NY rev (3m)41.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 26.21
P/FCF N/A
P/OCF N/A
P/B 3.77
P/tB 3.82
EV/EBITDA N/A
EPS(TTM)-1.3
EYN/A
EPS(NY)-1.15
Fwd EYN/A
FCF(TTM)-0.75
FCFYN/A
OCF(TTM)-0.75
OCFYN/A
SpS0.28
BVpS1.97
TBVpS1.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.35%
ROE -62.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-333.55%
ROA(5y)-244.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.69
Quick Ratio 14.4
Altman-Z 2.8
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)12.76%
Cap/Depr(5y)24.09%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-160%
EPS Next Y-1706.25%
EPS Next 2Y-275%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-20.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year124.69%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.86%
OCF growth 3YN/A
OCF growth 5YN/A